14M138: Editors Picks 2022: Arthritis & Rheumatology and Annals of the Rheumatic Diseases

Moderator(s)

• 

  Daniel Solomon, MD, MPH

  Brigham and Women's Hospital
  Newton, MA, United States

  Disclosure(s): AbbVie/Abbott: Grant/Research Support (Ongoing); Amgen: Grant/Research Support (Ongoing); CorEvitas: Grant/Research Support (Ongoing); moderna: Grant/Research Support (Ongoing)
• 

  Josef Smolen, MD

  Medical University of Vienna
  Vienna, Austria

  Disclosure(s): AbbVie: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Amgen: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); AstraZeneca: Grant/Research Support (Ongoing); Bristol Myers Squibb: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Galapagos-Gilead: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Janssen: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Merck-Sharp-Dohme: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Novartis: Grant/Research Support (Ongoing); Novartis-Sandoz: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Roche-Chugai: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Samsung: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); UCB: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

Presentations:

• 1:00 PM – 1:05 PM Eastern Time

  Arthritis & Rheumatology Editor Introduction
  

  Speaker: Daniel Solomon, MD, MPH – Brigham and Women's Hospital
• 1:05 PM – 1:15 PM Eastern Time

  Safety and Efficacy of Bimekizumab in Patients with Active Ankylosing Spondylitis/Psoriatic Arthritis: 3-Year Results from a Phase 2b Randomized Controlled Trial and its Open-Label Extension Study
  

  Speaker: Xenofon Baraliakos, MD – Rheumazentrum Ruhrgebiet Herne

  Speaker: Laura C. Coates, MD, PhD – University of Oxford
• 1:15 PM – 1:25 PM Eastern Time

  Smartphone Assisted patient Initiated Care Versus Usual Care in Patients with Rheumatoid Arthritis and Low Disease Activity: A Randomized Controlled Trial
  

  Speaker: Bart F. Seppen, MD – Vrije Universiteit | Reade
• 1:25 PM – 1:30 PM Eastern Time

  Q&A
  
• 1:30 PM – 1:35 PM Eastern Time

  Annals of the Rheumatic Diseases Editor Introduction
  

  Speaker: Josef Smolen, MD – Medical University of Vienna
• 1:35 PM – 1:45 PM Eastern Time

  Multi-trait and Cross-population Genome-wide Association Studies Across Autoimmune and Allergic Diseases Identify Shared and Distinct Genetic Component
  

  Speaker: Yukinori Okada, MD, PhD – Osaka University / The University of Tokyo / RIKEN
• 1:45 PM – 1:55 PM Eastern Time

  Risk of Major Adverse Cardiovascular Events with Tofacitinib versus Tumour Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis with or Without a History of Atherosclerotic Cardiovascular Disease: A Post Hoc Analysis from ORAL Surveillance
  

  Speaker: Maya Buch, MD, PhD – University of Manchester
• 1:55 PM – 2:00 PM Eastern Time

  Q&A